Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye disease At 450 mg Q4W, MHB018A …

![BIFOX ENTERS INTO AGREEMENTS TO ACQUIRE THE 550 MILLION TONNE[1] BAYOVAR 9 PHOSPHATE ROCK PROJECT IN PERU POSITIONING BIFOX TO BECOME ONE OF THE LEADING GLOBAL PHOSPHATE ROCK SUPPLIERS](https://i0.wp.com/mma.prnasia.com/media2/2996563/logo_Logo.jpg?fit=%2C&ssl=1)
![BIFOX ENTERS INTO AGREEMENTS TO ACQUIRE THE 550 MILLION TONNE[1] BAYOVAR 9 PHOSPHATE ROCK PROJECT IN PERU POSITIONING BIFOX TO BECOME ONE OF THE LEADING GLOBAL PHOSPHATE ROCK SUPPLIERS](https://i0.wp.com/mma.prnasia.com/media2/2996559/logo_Logo.jpg?fit=%2C&ssl=1)






